Rubedo Life Sciences' Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or "Zombie" Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Article content
Study is the first demonstration of senescent neurons driving neuropathic pain 1
Rubedo's proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets 2
Article content
Article content
SAN FRANCISCO — Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company's broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age. 1 Senescent cells, often called 'zombie' cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body. 1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and Lauren Donovan, PhD, and co-authored by Rubedo team members, including Chief Scientific Officer Marco Quarta, PhD, and Chief Technology Officer Alex Laslavic, was published in the May 14 th edition of Nature Neuroscience, a prestigious, peer-reviewed scientific journal, and will be featured on the cover of the May issue.
'In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue,' said Dr. Marco Quarta, Chief Scientific Officer of Rubedo Life Sciences.
Article content
Dr. Quarta said, 'We know that senescent cells, which increase as people age, drive chronic degenerative diseases and conditions. In this study, we were able to show for the first time that neurons can become senescent, fueling neuropathic pain in both mouse models and human dorsal root ganglia tissue. The bioinformatic validation provided as part of our broader ALEMBIC™ platform with SenTeCh™ chemistry technology helped to uncover this link between aging and neuropathic pain, and further corroborates our experimental observations that treatments targeting these senescent cells could offer meaningful benefits for people experiencing age-related conditions.' 1
Article content
About the Study
Article content
In the study, researchers found that injury to peripheral axons of dorsal root ganglion (DRG) neurons results in sensory dysfunction, such as pain. This occurs at higher rates in aged individuals. Furthermore, cellular senescence is common to both aging and injury, and contributes to this sensory dysfunction. Elimination of senescent cells results in pain improvement, indicating a potential target for new pain therapeutics. 1
Article content
'Chronic pain continues to be an area with high unmet need, especially among older adults. In this study, aging markedly increased the burden of senescent or 'zombie' neurons, which in turn worsened neuropathic pain severity. These insights demonstrate that selective targeting of senescent-like neurons may lead to novel strategies for the management of chronic pain,' 1 said Vivianne, L. Tawfik, MD, PhD, Associate Professor, Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, and the senior author of the study. 'We appreciate the valuable support and expertise from the Rubedo team during this research.'
Article content
About Rubedo Life Sciences
Article content
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – is set to begin Phase I clinical trials in Spring of 2025, marking the first ever GPX4 modulator to enter a human clinical trial. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Contact:
Rubedo Chief Business Officer Ali Siam
alisiam@rubedolife.com
781-974-9559
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
13 hours ago
- CBC
He can't quit him — easily. Why SpaceX could complicate the Trump-Musk split
Billions of dollars lost in government contracts. A slew of regulatory headaches. These are just some of the ramifications Elon Musk could face over his fallout with U.S. President Donald Trump. The two men may have personally split, at least for now. But if Trump is seeking to retaliate against the tech billionaire, severing the relationship between Musk's many companies and the U.S. government could prove difficult, analysts say. "I would say the president has more cards than Musk does, but it doesn't mean that [Musk] doesn't have any," said Peter Hays, a lecturer of space policy and international affairs at George Washington University's Space Policy Institute. Both sides have "all kinds of leverage on each other," added Dan Grazier, senior fellow and program director at the D.C.-based Stimson Center, a think-tank focused on international security. The public fallout came after Musk repeatedly criticized Trump's spending bill. Trump eventually lashed back, posting on Truth Social that the easiest way to save "Billions and Billion of Dollars" would be to "terminate Elon's Governmental Subsidies and Contracts." However, those threats might not be so simple to implement. SpaceX, satellite contracts SpaceX has $15 billion US worth of contracts from NASA for the company's Falcon 9 rockets and its development of the multipurpose Starship rocket system, tapped to land NASA astronauts on the moon this decade. The company has also been awarded billions of dollars to launch most of the Pentagon's national security satellites into space while it builds a massive spy satellite constellation. That's why, if Trump cancels those contracts, SpaceX would have to seriously rethink its business model, Grazier says. Musk "needs the government to keep his company operating as they are," he said. But the U.S. government is also reliant on SpaceX, he says. For example, it's the only U.S. company capable right now of transporting crews to and from the International Space Station, using its four-person Dragon capsules. "Trump needs Elon Musk in pretty much the exact same way that Elon Musk needs President Trump, as far as SpaceX goes," Grazier said. "It's not like the United States has a credible alternative to SpaceX right now as far as space launch goes," he said. "And the United States needs reliable space launch capabilities." WATCH | F eud explodes into public view: Threats, insults as Trump-Musk feud explodes into public view 1 day ago Duration 2:27 Tearing up SpaceX contracts would have a huge domino effect across a lot of the government's critical functions in space, according to Clayton Swope, senior fellow at the Center for Strategic and International Studies. And those functions are "most closely centred around the Pentagon and NASA," he told Bloomberg News. But if Trump holds off on cancelling SpaceX contracts, and is looking for another way to poke at Musk, he could put the squeeze on Musk's companies through the government's regulatory agencies, some experts say. "Those can all be leverage points for the administration," said Cary Coglianese, director of the University of Pennsylvania's Penn program on regulation. Last year, Musk was waging at least 11 separate regulatory or legal battles with the Biden administration or independent federal agencies related to his business empire, according to NBC News. This might have been why, in part, Musk eventually endorsed Trump, who had pledged during the presidential campaign to slash regulations. How Trump's tax bill ignited his feud with Musk | Hanomansing Tonight 1 day ago Duration 7:21 Yet Trump could now pressure those same agencies to make Musk's life difficult. Just some of the regulators Musk's business empire must deal with include the Federal Communications Commission for his satellite internet service Starlink, the National Highway Traffic Safety Administration for Tesla, and the Federal Aviation Administration (FAA) for SpaceX. The FAA, under pressure from Trump, or to curry his favour, could say it's not going to approve any SpaceX launch permits, says Roger Nober, director of the Regulatory Studies Center, also at George Washington University. For Tesla, for example, Trump could pressure regulators to deny necessary approvals of its autonomous driving program, or could renew investigations into the safety of its full self-driving software, some analysts told ABC News. "If full self-driving were to be invalidated, that would be a huge hit to Tesla stock and to Musk," Gordon Johnson, CEO and founder of the data firm GLJ Research, told ABC. Although the courts shouldn't tolerate such actions if they are shown to be vindictive, the president wouldn't necessarily need a "litigation-proof strategy to really mess up" Musk's life, Coglianese said. It could still be "very painful and problematic" for Musk, while courts sorted out the issues, he said. "And if Musk's operations get delayed or disrupted, that can mean real money." Nober says he believes that any lasting regulatory change against Musk's companies would be difficult to implement, given his very public spat with Trump and that the president said he's going to punish his one-time friend. "If they then initiate regulatory action that's intended punish any of Musk's business… it's going to be vulnerable to challenge on the theory that it was arbitrary," he said. However, there may be other minor administrative regulatory roadblocks that government agencies could impose on Musk that would be difficult to challenge in court, Nober says. "They can make life difficult" for Musk, he said. On Thursday, amid their war of words, shares of Tesla plunged more than 14 per cent, leaving $150 billion US of the electric automaker's value erased by the end of trading day. The plunge was probably because Tesla, like a lot of Musk's companies, have a lot of little things they deal with, with a lot of regulatory bodies, Nober says. "Just making those more difficult, or slowing them down, or reviewing them, or taking longer to turn things around, has a cumulative impact," he said.
CBC
13 hours ago
- CBC
CO2 levels just broke another record. Here's what that means
Social Sharing When man first walked on the moon, the carbon dioxide concentration in Earth's atmosphere was 325 parts per million (ppm). By 9/11, it was 369 ppm, and when COVID-19 shut down normal life in 2020, it had shot up to 414 parts ppm. This week, our planet hit the highest levels ever directly recorded: 430 parts per million. For 67 years, the observatory on Hawaii's Mauna Loa volcano has been taking these measurements daily — tracking the invisible gas that is building up in our atmosphere and changing life on Earth. The record is known as the Keeling Curve. Charles David Keeling began those recordings, some of the first in the world to measure CO2 concentration over time. His son, Ralph Keeling, born one year before the observatory opened, has witnessed the rapid increase firsthand over his lifetime. "I was a teenager when I first started to appreciate what my father was doing and how it might be significant," Keeling told CBC News. Back then it was around 330 ppm. Keeling, a geochemistry professor at Scripps Institution of Oceanography at the University of California, San Diego, took over the research once his father passed away in 2005. "This problem is not going away, and we're moving further and further into uncharted territory, and almost certainly, very dangerous territory." Why CO2 matters The build up of carbon dioxide in the atmosphere isn't visible to the naked eye, but its concentration matters because of the greenhouse effect. Like the glass walls that trap heat from the sun in an actual greenhouse, gases in our atmosphere such as CO2 and methane also trap heat from the sun. At the start of the Industrial Revolution, ice core samples show CO2 levels were around 280 parts per million but as they rose, warming has increased by about 1.3 C over the pre-industrial average. That's led to rising temperatures and leading to more frequent and extreme weather, like heat waves, floods, wildfires and droughts. While many have heard about the goals of limiting warming to 1.5 C or 2 C above pre-industrial levels, there have also been efforts to return CO2 levels to below 350 parts per million, as a key part of limiting the damage from climate change. The record highs have continued though. Just in the last year, CO2 readings from May have increased more than three parts per million — that many more molecules of CO2 trapping heat and contributing to warming. "We know why it's rising faster than ever, it's because we're burning more fossil fuels each year," said Keeling. Direct link to fossil fuels Damon Matthews, a climate scientist and professor at Concordia University in Quebec, also says he's concerned and isn't surprised that there are new records every year. "If we want to actually stabilize CO2 levels in the atmosphere, we would need to cut global emissions by more than 50 per cent, and we're nowhere near doing that," he said, adding that there are other gases at play but CO2 is the dominant influence. "Every May, we're going to see a new record of atmospheric CO2, until we actually make a lot more progress on climate mitigation than we have today." The annual cycle, peaking in late spring in the northern hemisphere, is tied to plant photosynthesis — CO2 concentrations drop in the summer as plants absorb the gas and release oxygen. In 2021, the International Energy Agency said that if the world wants to limit global warming and reach net-zero by 2050, there could be no new coal, oil or gas projects. Matthews is part of Canada's net-zero advisory body and says he's seen some progress in decreasing CO2 emissions the last few years, but not enough. He says Europe's emissions have been going down for decades, and that last year CO2 emissions in China didn't increase. However, he says Canada still lags behind other countries, and the U.S. is trending the other way. "There's lots of policy options, certainly focusing on expanding the oil and gas industry in Canada right now is not going to get us where we need to go in terms of climate," he said. "We just need to stop arguing about whether it's a priority and start doing the things that we know will help to solve the problem."
Globe and Mail
20 hours ago
- Globe and Mail
B.C. launches $5-million ad campaign to recruit American doctors, nurses
British Columbia has launched a six-week, $5-million campaign of targeted advertisements to recruit doctors and nurses in the United States, citing 'chaos' under the Trump administration to lure them north. The Ministry of Health said the campaign launched on Monday was being shown on thousands of advertising screens in Washington, Oregon and California, at locations within a 16-kilometre radius of health care facilities, as well as on podcasts and Netflix shows. B.C. Health Minister Josie Osborne said at a news conference it was a step B.C. needed to 'take right now' to attract physicians, nurses and other health care workers, and the province would do everything in its power to ease their transition. 'This will help supercharge our overall recruitment campaign to attract U.S. health care workers to B.C.,' she said. Opinion: How to win a trade war Fentanyl czar focused on combatting opioid trade, despite tariff distraction In one of the ads, a disgruntled-looking woman in hospital scrubs listens to 'more news from Washington' before the scene cuts to outdoor views of British Columbia, and listeners are urged to 'follow your heart' to the province. Osborne said the campaign was expected to reach about 250,000 health care workers. She said B.C. was 'taking advantage of the uncertainty and chaos' in the United States after the election of President Donald Trump by reaching out to health workers who shared the values of the province's health care system. One ad says recruits can 'practice evidence-based care' in B.C., while another promises 'universal health care that puts people first.' Looming over these efforts is the question of whether B.C.'s public single-payer system offers sufficient financial incentives. Osborne said it was difficult to directly compare physician salaries in B.C. with those in the United States. 'But I can say that with some of the recent changes we've made, and how we pay family doctors, we know that we have competitive salaries,' she said. 'We also know that we offer very competitive salaries for nursing. We offer some of the highest nursing wages in Canada. We also know, though, that doctors are not just motivated by dollars and cents.' Osborne said nearly 1,600 health care providers had already expressed an interest in moving to B.C. even before the ads launched. These included 700 doctors and 500 nurses, but she could not say how many had made it to B.C. 'We're going to do everything we can to attract as many physicians and nurses as possible,' she said without giving a specific target number. 'Ultimately, the success is measured by what people experience in their communities,' she added. She said B.C. would eventually expand international recruitment to other jurisdictions, likening the process to hitting a target. 'We've got the U.S. right in the centre, the bull's eye, and then right outside in the next rings, are countries like the United Kingdom,' she said. 'That's where we'll be focusing our efforts next.'
